Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.08M | 2.00M | 0.00 | 297.00K | 3.32M | 2.30M |
Gross Profit | 2.08M | 2.00M | 0.00 | 232.00K | 2.85M | 2.30M |
EBITDA | -3.47M | -3.63M | -12.59M | -18.18M | -55.20M | -81.27M |
Net Income | -2.94M | -3.06M | -21.02M | -43.78M | -51.66M | -72.67M |
Balance Sheet | ||||||
Total Assets | 9.85M | 9.57M | 13.37M | 18.08M | 59.33M | 115.38M |
Cash, Cash Equivalents and Short-Term Investments | 3.64M | 3.23M | 7.57M | 13.38M | 53.96M | 54.40M |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.73M |
Total Liabilities | 1.07M | 725.00K | 2.09M | 7.63M | 11.09M | 55.88M |
Stockholders Equity | 8.78M | 8.85M | 11.29M | 10.45M | 48.25M | 59.49M |
Cash Flow | ||||||
Free Cash Flow | -3.43M | -4.33M | -21.25M | -40.61M | -36.52M | -74.01M |
Operating Cash Flow | -3.43M | -4.33M | -21.25M | -40.61M | -36.52M | -72.49M |
Investing Cash Flow | 0.00 | 0.00 | 10.40M | 0.00 | 1.46M | 18.00K |
Financing Cash Flow | 1.38M | 0.00 | 5.02M | 29.00K | 30.79M | 28.09M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | ¥341.99B | 10.89 | -2.99% | 2.57% | 11.76% | -9.96% | |
48 Neutral | $3.56M | ― | -205.75% | ― | 2552.29% | 60.70% | |
47 Neutral | $11.14M | ― | -31.48% | ― | ― | 86.52% | |
44 Neutral | $10.41M | ― | -9999.00% | ― | -63.20% | 15.71% | |
43 Neutral | $16.80M | ― | -362.79% | ― | 32.45% | 39.31% | |
40 Underperform | $9.96M | ― | -59.80% | ― | 157.63% | 40.52% | |
34 Underperform | $8.47M | ― | -126.03% | ― | -100.00% | -27.44% |
Cyclerion Therapeutics has renegotiated its praliciguat license agreement with Akebia, securing $1.75 million in upfront and near-term payments while reducing operating expenses to focus on building its CNS pipeline. Additionally, Cyclerion entered into a license option agreement for olinciguat with CVCO Therapeutics, marking significant steps in monetizing its legacy assets and positioning itself for future growth by acquiring new CNS assets.